Breast cancer associated with BRCA1 and BRCA2 gene mutations differs from non-BRCA tumors in several respects. We determined whether there was any difference in CCND1 (11q13) and ZNF217 (20q13) gene amplification with respect to BRCA status. Of 40 breast cancer samples examined, 15 and 9 were from BRCA1 and BRCA2 mutation carriers, respectively, and 16 from patients without mutation. Fluorescence in situ hybridization showed that eight tumors exhibited CCND1 amplification (20%; 3 BRCA1, 3 BRCA2, 2 non-BRCA). ZNF217 amplification was observed in three of 38 cases (8%; 2 BRCA1, 1 non-BRCA). There was no significant difference in CCND1 and ZNF217 amplification between BRCA1, BRCA2 and non-BRCA tumors. CCND1 amplification was associated with decreased disease-free (P = 0.045) and overall survival (P = 0.015). BRCA1 tumors with CCND1 amplification were estrogen receptor negative, in contrast to CCND1 amplified BRCA2 and non-BRCA tumors, suggesting that concurrent CCND1 amplification and estrogen and progesterone receptor negativity may predict germline BRCA1 gene mutation. All ZNF217 amplified tumors were of the medullary histological type (P = 0.002). There was no statistical correlation between CCND1 and ZNF217 amplification and estrogen receptor, progesterone receptor, and ERBB2 expression and TNM classification. CCND1 amplification did not correlate with EGFR expression.
Genome alterations and aneuploidy are frequently found in breast cancer. Indeed, several chromosomal regions of amplification have been identified and characterized, the most frequent being 8p12, 8p24, 11p13 and 17q12 [1] . Each of these is found in 10 to 25% of cases [1] . Amplification at 20q13 is slightly less frequent and occurs in around 5 to 12% of cases [2] . Several genes appear to be involved in the 8p12 amplification, including the RAB11FIP1 and FGFRI genes, while the MYC gene is involved in 8q24 amplification, the CCND1 gene in 11q13, the ERBB2 gene in 17q12, and the MYBL2, ZNF217 and STK6 genes in 20q13 amplification [reviewed in 2] . Amplification of ERBB2 is a factor of poor prognosis and amplification of CCND1 is more frequent in tumors with positive estrogen receptor (ER) status. Aneuploidy and aggressive behavior are often associated with 20q13 amplification [3, 4] . Women with germline mutations in the BRCA1 and BRCA2 tumor suppressor genes are known to be predisposed to breast and ovarian cancer [5] . Breast cancer associated with BRCA1 and BRCA2 gene mutations differs from other breast cancer cases in several aspects. Most BRCA1 carcinomas have a basal cell phenotype, a subtype of high-grade, highly proliferating, triple-negative breast cancer (i.e. with negative ER, progesterone receptor (PR), and ERBB2 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog) status), characterized by the expression of basal or myoepithelial markers such as basal keratins, P-cadherin and epidermal growth factor receptor (EGFR) [6, 7] . This phenotype is rarely found in BRCA2 carcinomas, which are of a higher grade than sporadic age-matched controls but tend to be ER and PR positive [7] [8] [9] [10] . An infrequent loss of PML protein expression and a more frequent aberrant reduction in ATM protein expression have been described among BRCA1 tumors [11, 12] . In addition, the expression of the cell-cycle proteins cyclin A, B1 and E has CCND1 and ZNF217 gene amplification is equally frequent in BRCA1 and BRCA2 associated and non-BRCA breast cancer P. PLEVOVA 1, 2 , D. CERNA 1 been associated with the BRCA1 phenotype, whereas p27 expression has been associated with BRCA2 carcinomas [7] . In almost all studies, no significant difference has been reported in p53 status between BRCA1, BRCA2 and sporadic tumors, BRCA1 and BRCA2 tumors being predominantly p53 positive [13] . Similarly, no significant difference has been found in the frequency of cathepsin D, bcl-2, p21, brc-2, proliferating cell nuclear antigen (PCNA), cyclin E, catepsin E, E-cadherin and beta-catenin expression [14] [15] [16] .
While two studies have been published that determine CCND1 gene amplification with respect to BRCA status, their results are contradictory [16, 17] . Amplification of the ZNF217 gene in association with BRCA1 and BRCA2 gene mutations has not yet been studied.
The aim of this study was to determine whether there is any difference in CCND1 (11q13) and ZNF217 (20q13) gene amplification in breast cancer of women with and without the BRCA1 or BRCA2 gene mutation and whether CCND1 and ZNF217 gene amplification correlates with any clinical or histopathological characteristics.
Materials and methods
The study population comprised 40 breast cancer samples from 40 unrelated female patients, of whom 15 were BRCA1 germline mutation carriers, 9 were BRCA2 germline mutation carriers and 11 were patients without a BRCA1 or BRCA2 germline mutation. Formalin fixed paraffin-embedded tumor samples were studied. Clinical data and histological findings were found in the health care documentation. Unfortunately, these data were not available in all the patients and in some patients, there was not enough material to perform immunohistochemical analyses.
The tumors were classified into the following five histological categories: ductal carcinoma grade 1 (low grade), 2 (medium grade) and 3 (high grade), lobular carcinoma and mucinous carcinoma. The TNM (Tumor, Node, Metastasis) stage was classified according to the 6th edition of "TNM classification of malignant tumours" [18] .
Indirect immunohistochemistry was used to evaluate ER, PR, PCNA, ERBB2 and EGFR expression. Prior to immunostaining, heat-induced antigen retrieval was performed by treatment in a microwave oven. Mouse monoclonal antibodies against estrogen receptor α (clone 1D5; DakoCytomation, Coppenhagen, Denmark), progesterone receptor (DakoCytomation, Denmark), PCNA (clone PC10, DakoCytomation, Denmark) and EGFR (NeoMarkers, California, USA) were used with the EnVision TM amplification system (DakoCytomation, Denmark). For ER, PR and PCNA, samples with less than 10% positive cells were considered negative (0), those with 10−25% of positive cells as weakly positive (1) and intense (3+) [19] . ERBB-2 status was evaluated through immunohistochemistry using the 0−3+ score as suggested by the HercepTest kit scoring guidelines (DakoCytomation, Denmark).
Formalin-fixed, paraffin-embedded tumor tissue was cut into 3 µm slices, placed on SuperFrost Plus slides and dried at 56°C overnight for fluorescent in situ hybridization (FISH). The slides were deparaffinized using the Paraffin Pretreatment Reagent Kit of Vysis Inc. (Downers Grove, Illinois, USA). Gene amplification was primarily analyzed using commercial probes supplied by Vysis Inc. (Downers Grove, USA). The directly labeled specific LSI Cyclin D1 (11q13; Spectrum Orange-labeled) and centromeric CEP11 (11p11.11-q11; Spectrum Green-labeled) probes were used for CCND1 amplification. ZNF217 amplification was detected using the LSI 20q13 (20q13.2; Spectrum Orange-labeled) and telomeric TelVysion 20p (20ptel; Spectrum Green-labeled) probes or the centromeric Satellite Enumeration Probe SE 20 (D20Z1; Spectrum Green-labeled) from Kreatech (Amsterdam, the Netherlands). All analyses were performed according to the manufacturers´ instructions. In each case, we evaluated 50−100 non-overlapping interphase nuclei with preserved morphology. The slides were viewed with an Olympus BX60 fluorescence microscope with three one-band pass filters and the images captured with a CCD camera, whereupon the images were filtered and processed using the Lucia software (Laboratory Imaging Ltd., Prague, Czech Republic). The copy number of the target genes and internal control for each cell was determined under 1 500x magnification. The sample was determined as carrying an amplification of CCND1 or ZNF217 gene if the number of gene probe signals divided by the number of centromere or telomere signals, respectively, was ≥1.5 [20] (Figure No. 1). The study was undertaken blind, the laboratory staff undertaking the FISH analysis (DC, AB) was not aware of the BRCA status, clinical or histopathological characteristics of the patients involved.
Statistical analysis: Fisher´s exact test was used to correlate gene amplification with BRCA status, histological grade, ER, PR, ERBB2, EGFR expression and TNM classification. Correlation with the age of patients was tested using the two-sample t−test. Disease-free and overall survival curves were derived from Kaplan-Meyer estimates and compared using the longrank test. A P value (two sided) of <0.05 was considered as significant.
Results
CCND1 amplification was found in eight of the 40 samples (20%) and ZNF217 amplification in three of 38 samples (8%). The amplification rates of the CCND1 and ZNF217 genes in the breast cancer samples in relation to BRCA1 and BRCA2 gene mutation status and other patient characteristics are summarized in Table 1 .
No significant difference was observed in CCND1 amplification between the BRCA1, BRCA2 and non-BRCA groups (P = 0.464; BRCA1 versus non-BRCA, P = 0.654; BRCA1 versus BRCA2, P = 0.312; BRCA2 versus non-BRCA, P = 0.635). Similarly, no significant correlation was observed between CCND1 amplification and age of patients (P = 0.763), histological typing (P = 0.160), ER (P = 0.915), PR (P = 0.854), PCNA (P = 0.121), ERBB2 (P = 0.871), and EGFR expression (P = 1.000) or with TNM classification (P = 0.905, 0.206 and 0.100, respectively, for pT, pN and pM). CCND1 amplification did show a significant correlation with decreased overall survival (P = 0.015). In CCND1-amplified cancer patients, the average overall survival time was 98 months (95% CI: 43−153 months) and median survival time 69 months (95% CI: 56−82 months), as opposed to non-CCND1-amplified cancer patients, where the average overall survival time was 181 months (95% CI: 148−213 months). CCND1 amplification was also significantly correlated with decreased disease-free survival (DFS) (P = 0.045). In CCND1-amplified cancer patients, the average DFS was 91 months (95% CI: 57−125 months) and median DFS 120 months (95% CI: 20-220 months), as opposed to non-CCND1 amplified patients where average DFS was 199 months (95% CI: 175−222 months). No correlation was observed between CCND1 amplification and ER and PR status. Although the number of samples was too low to calculate statistical significance, all BRCA1 patients with CCND1 amplified tumors were ER and PR negative, whereas all BRCA2 and non-BRCA patients with CCND1 amplified tumors were ER and PR positive.
As regards ZNF217 amplification, no significant differences were observed between the BRCA1, BRCA2 and non-BRCA groups (P = 0.773; BRCA1 versus non-BRCA, P = 1.000; BRCA1 versus BRCA2, P = 1.000; BRCA2 versus non-BRCA, P = 0.502). All three ZNF217 amplified tumors were of the medullary histological type and were negative for ER and PR. Correlation with histological typing was statistically significant (P = 0.002). There were no significant correlations between ZNF217 amplification and ER (P = 0.777), PR (P = 0.799), PCNA (P = 0.522) and ERBB2 expression (P = 0.404), or with TNM classification (P = 0.592, 1.000, and 1.000, respectively, for pT, pN and pM). Due to the low number of ZNF217-amplified tumors, it was not possible to assess any correlation with age, EGFR, disease-free and overall survival.
Discussion
We observed CCND1 amplification in eight of the 40 tumors examined (20%). This detection rate is similar to those of a number of other studies, which have observed CCND1 amplification in between 10-20% of samples. CCND1 amplification was found in 18% of 88 cases of ductal breast cancer in situ [21] , for example, and in 9.6% of 613 breast cancer cases studied by Elsheikh et al. [22] . Similarly, Letessier et al. As regards BRCA status, there have been more studies focused on cyclin D1 expression than on CCND1 gene amplification. Most of these studies have exhibited significantly lower cyclin-D1 expression levels in BRCA1-mutation carriers than in sporadic tumors [1, 9, 28] . The percentage of cyclin D1 expression ranges from 5 to 33% in BRCA1 tumors, from 27 to 57% in BRCA2 tumors and from 35 to 55% in non-BRCA tumors [7, 16, 24, 25, 26] . No difference in cyclin D1 expression was found in 157 hereditary breast cancers with BRCA2 germline mutations and 314 control tumors negative for the BRCA1 and BRCA2 mutations [8] .
Cyclin D1 is a member of a family of proteins that functions primarily in the cell division cycle, regulating the activity of cyclin-dependent protein kinases [27] . Cyclin D1 is essential for G1 phase progression [28] and is implicated in the pathogenesis of several human malignancies, including breast carcinoma [29, 30] . Cyclin D1 probably mediates many of the known hormonal effects on cell proliferation in breast epithelial cells [28] . In mice engineered to be cyclin D1 deficient, the normal mammary epithelial proliferative response to pregnancy is ablated, demonstrating in vivo the critical role that cyclin D1 plays in normal epithelial proliferation [31] . Transgenic mice overexpressing cyclin D1 in the mammary epithelium are characterized by abnormal mammary cell proliferation, including development of mammary adenocarcinomas [21, 32] .
Cyclin D1 is induced by estrogen and its association with ER positivity has been clearly demonstrated in breast cancer [33, 34] . In crossed ERα-overexpression mice with cyclin D1 knockout mice, mammary gland morphogenesis was completely interrupted [33] . ERα-overexpressing cells are absolutely dependent on cyclin D1 for proliferation [35] . These results have implications for tumors with ER overexpression and are supported by the results of clinical studies demonstrating that cyclin D1 overexpression correlates with ER positivity in breast cancer [22] .
According to in vitro studies, cyclin D1 expression is dependent on ERα signaling [34]. ERα-negative tumors and tumor cell lines that also show over-expression of cyclin D1 have also been found, suggesting that, in addition to ERα signaling, cyclin D1 expression is under the control of other signaling pathways. These pathways may even be over-expressed in the ERα-negative cells [34] . ER negativity is typical of tumors from BRCA1 mutation carriers. Although the rate of cyclin D1 positive cases is lower in BRCA1 tumors than in sporadic tumors, they still represent some 5 to 33% of all positive cases [7, 20, 24, 25, 36] . The aforementioned alternative pathways of cyclin D1 overexpression induction may be involved in these positive cases. Some cases may also be explained by CCND1 amplification, which is a non-ER dependent mechanism.
Whereas all BRCA2 and non-BRCA tumors with CCND1 amplification in our study were ER positive, all three CCND1 amplified BRCA1 tumors were ER negative. Our results suggest, therefore, that if a tumor has both CCND1 amplification and ER negativity, it may be associated with a BRCA1 mutation. Thus, positive CCND1 amplification and ER negativity may represent further features that may have implication for performing a BRCA1 gene mutation analysis.
Similar to our results, two previous studies have noted a correlation between CCND1 amplification and decreased survival of patients [1, 37] .
Amplification at 20q13 occurs in a variety of tumor types and is associated with aggressive tumor behavior [38] . ZNF217, a Kruppel-like zinc finger transcription factor with oncogenic potential, is localized on this chromosomal region and is known to immortalize breast epithelial cells and to suppress cell death [39] .
We found a weak ZNF217 amplification in three of 38 (8%) tumors. All the tumors with ZNF217 amplification were ER and PR negative and all of them were of the medullary histological type. Ginestier et al.
[2] observed 36 of 466 (8%) tumors with 20q13 (MYBL2, ZNF217 or SKT6) amplification, ZNF217 being amplified in 31 cases (7%). In nine of the 36 samples, ZNF217 was amplified without amplification of the two other loci. ZNF217-only amplified tumors were associated with an absence of lymph node metastasis and, paradoxically, with a poor prognosis, whereas tumors with amplification at two or three loci were associated with high histological grade, presence of lymph node metastasis and, paradoxically, with a good prognosis. A strong correlation existed between the two classes and the ER status of tumors, with more ER-negative tumors in the ZNF217-only amplified group as compared with amplification at two or three loci.
Two of the ZNF217 amplified tumors were from BRCA1 gene mutation carriers and one from a patient with no BRCA1 or BRCA2 mutation. There was no significant difference in ZNF217 amplification between the groups. In breast tumors from BRCA1 germline mutation carriers, high levels of ERBB2 oncogene amplification do not occur, or occur only rarely. In contrast, ERBB2 is highly amplified in approximately 15% of sporadic breast tumors [41] . There are several possible mechanisms to explain why ERBB2 is never highly amplified in the background of a BRCA1 germ-line mutation. One is that impaired BRCA1 may functionally suppress amplification. BRCA1 contains several functional domains that interact directly or indirectly with a variety of molecules [42] , and is likely to serve as an important central component in multiple biological pathways [43] , including processes involved in gene amplification. Some gene amplification processes require functional nonhomologous end-joining [reviewed in 9, 44] . Loss of this repair pathway in BRCA1 mutant tumors may limit gene amplification [reviewed in 9]. Our results do not support this hypothesis, however, as we found CCND1 and ZNF217 gene amplification in similar proportions of BRCA1, BRCA2 and non-BRCA tumors. Other possible mechanisms that block ERBB2 amplification in BRCA1 tumors are more probable, therefore, including co-deletion of one allele of ERBB2 and its nearby sequences during loss of heterozygosity at the BRCA1 locus, thus disabling gene amplification, which requires the presence of both alleles of the gene or amplification suppression through an indirect structural mechanism, such as abnormal chromatin conformation on 17q [9, [45] [46] [47] .
In none of our samples, co-amplification of CCND1 and ZNF217 was observed. Our study sample was too small, however, and the number of loci analyzed too incomplete, to Co ; in all other cases, co-amplification was detected with one or more other loci (8p12, 8q24, 11q13 or 17q12) . The 11q13 region was never observed to be amplified alone [23] . Our CCND1 or ZNF217 amplified tumors, therefore, may also be amplified at another locus.
In conclusion, our results show that CCND1 amplification can be associated with a worse outcome of breast cancer. Concurrent CCND1 amplification and estrogen and progesterone receptor negativity may be a predictor of germline BRCA1 gene mutation. This observation should be confirmed in a larger study, however. The equal frequency of CCND1 and ZNF217 amplification in BRCA1, BRCA2 and non-BRCA breast cancer suggests that loss of functional BRCA1 protein may not limit gene amplification.
